title: Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension.
abstract: The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine. The BNP secretory rates from the ventricle in enalapril- and MK-954-treated DOCA-salt SHR were decreased to approximately 50% of those in untreated DOCA-salt SHR. The BNP secretory rate from the ventricle was positively correlated with ventricular weight in untreated and treated DOCA-salt SHR. In contrast, acute administration of captopril or MK-954 did not decrease the BNP secretory rate from the heart. Results suggest that the decrease in plasma BNP after enalapril and MK-954 is attributed to a decline in the secretion from the ventricle but not from the atrium. The reduction in ventricular mass appeared to be related to this decline.
authors.affiliation: First Department of Internal Medicine, Osaka City University Medical School, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kohno
authors.forename: T
authors.initials: T
authors.lastname: Fukui
authors.forename: T
authors.initials: T
authors.lastname: Horio
authors.forename: K
authors.initials: K
authors.lastname: Yokokawa
authors.forename: K
authors.initials: K
authors.lastname: Yasunari
authors.forename: M
authors.initials: M
authors.lastname: Yoshiyama
authors.forename: N
authors.initials: N
authors.lastname: Kurihara
authors.forename: T
authors.initials: T
authors.lastname: Takeda
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D001806:Blood Urea Nitrogen; D006332:Cardiomegaly / Q000209:etiology / Q000503:physiopathology*; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000097:blood; D003900:Desoxycorticosterone; D004656:Enalapril / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006830:Hydralazine / Q000494:pharmacology*; D006974:Hypertension, Malignant / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D007093:Imidazoles / Q000494:pharmacology*; D019808:Losartan; D008297:Male; D020097:Natriuretic Peptide, Brain; D009419:Nerve Tissue Proteins / Q000097:blood*; D051381:Rats; D011918:Rats, Inbred SHR; D012982:Sodium, Dietary; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D001713:Biphenyl Compounds; D007093:Imidazoles; D009419:Nerve Tissue Proteins; D012982:Sodium, Dietary; D013777:Tetrazoles; D020097:Natriuretic Peptide, Brain; D006830:Hydralazine; D003900:Desoxycorticosterone; D004656:Enalapril; D009320:Atrial Natriuretic Factor; D003404:Creatinine; D019808:Losartan